Purpose

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

Condition

Eligibility

Eligible Ages
Between 18 Years and 55 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of TRD

Exclusion Criteria

  • Other comorbidities

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Low dose
Low dose Psilocybin
  • Drug: Psilocybin
    Dose-ranging
Experimental
Medium dose
Medium dose Psilocybin
  • Drug: Psilocybin
    Dose-ranging
Experimental
High dose
High dose Psilocybin
  • Drug: Psilocybin
    Dose-ranging

Recruiting Locations

UT Center of Excellence on Mood Disorders, University of Texas Health Science Center
Houston, Texas 77054
Contact:
Valeria Cuellar
Valeria.A.Cuellar@uth.tmc.edu

More Details

NCT ID
NCT03775200
Status
Recruiting
Sponsor
COMPASS Pathways

Study Contact

Susan Stansfield, PhD
+44-7780-523013
sue@compasspathways.com

Detailed Description

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.